Breaking News Headlines Today | Ground News

See every side of every news story

hcplive.com image

News from hcplive.com

See all of hcplive.com news coverage in one place. Discover how hcplive.com’s media bias informs their coverage and compare with thousands of other news outlets.

Ground News has come across 877 headlines reported on by hcplive.com during the past 3 months.

hcplive.com’s aggregated media bias check is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

Is hcplive.com credible or reliable? Our Factuality score answers both of those questions. When it comes to hcplive.com, we’ve assigned a Unknown factuality rating. Ratings are assigned by aggregating scores from Ad Fontes Media and Media Bias/Fact Check.

Information about hcplive.com

Where is hcplive.com located?hcplive.com's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top hcplive.com News

Orsini Selected as Specialty Pharmacy Partner for KalVista's EKTERLY® (Sebetralstat)

Pharma · Fergus Falls

Orsini Selected as Specialty Pharmacy Partner for KalVista's EKTERLY® (Sebetralstat)

92% Center coverage: 12 sources

EKTERLY is an FDA-approved oral therapy for the on-demand treatment of hereditary angioedema (HAE)See the Story

Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX ...

Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX ...

100% Center coverage: 5 sources

SAN FRANCISCO and BOSTON, July 06, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with the potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for…See the Story

Khosla Ventures Targets Nearly $4 Billion in New Funds

FDA · United States

Khosla Ventures Targets Nearly $4 Billion in New Funds

75% Center coverage: 4 sources

KalVista has brought the first oral, on-demand treatment for hereditary angioedema attacks to the US market See the Story

'Groundbreaking' Drug Could Slow Down Progression of Type 1 Diabetes

67% Right coverage: 3 sources

Teplizumab trains the immune system to stop attacking pancreatic cells, delaying the need for insulin by an average of three yearsNHS · United Kingdom See the Story

J&J Submits sNDA to FDA for Lumateperone (CAPLYTA) to Prevent Schizophrenia Relapse

Johnson & Johnson seeks FDA approval for lumateperone (CAPLYTA) to significantly reduce schizophrenia relapse risk. Company submits an sNDA.Johnson & Johnson · United States See the Story

The Role of Biologic Therapies in Optometry with Walt Whitley, OD, MBA

Whitley speaks to the plethora of available biologics, the choice paralysis that can accompany the wide range of options, and the future of the industry.Read Article

Positive 16-Week Findings Highlighted on Tralokinumab for Atopic Dermatitis on the Hands

These ADHAND trial data highlight the results of tralokinumab in those with atopic dermatitis on the hands who are candidates for systemic therapy.Healthcare See the Story

Artificial Intelligence in Cataract Surgery and Optometry at Large with Harvey Richman, OD, and Rebecca Wartman, OD

Drs. Richman and Wartman discuss the benefits of using predictive and diagnostic AI, while cautioning about the implicit risks of overreliance on early, imperfect technology.Artificial Intelligence Read Article

Nephrology First Half Recap: 2025

The first half of 2025 recap for nephrology spotlights renal FDA action, ERA 2025 Congress coverage, and updates in xenotransplantation.Read Article

Skin of Color Savvy: UV Safety in Skin of Color, with Rebecca Vasquez, MD and Adewole Adamson, MD, MPP

This clinical episode of Skin of Color Savvy features a discussion on UV safety and photo protection in patients with skin of color.Maryland · Maryland Read Article

Efficacy of Current Standard-of-Care Treatments for Resistant Hypertension

Panelists discuss how standard ACE therapy leaves multiple pathways unblocked in resistant hypertension, with spironolactone being the most evidence-based fourth-line therapy despite limitations, while emerging therapies target sympathetic nervous system overactivity, aldosterone excess, and endothelin-mediated vasoconstriction.Read Article

Breaking News Topics Related to hcplive.com